Timing of Apixaban Initiation After Pulmonary Embolism

Initial Management of PE

The European Society of Cardiology recommends immediate anticoagulation when PE is suspected or confirmed, as this reduces mortality and morbidity 1, 3
For patients with PE who are eligible for a NOAC, a NOAC such as apixaban is preferred over vitamin K antagonists 4, 5
Parenteral anticoagulation with LMWH or fondaparinux is preferred over UFH for initial treatment in most cases, except in patients with severe renal impairment or those being considered for thrombolysis 1, 6

Apixaban should be administered at 10 mg twice daily for the first 7 days 2
After the initial 7-day period, the dose should be reduced to 5 mg twice daily for the remainder of the treatment period 2

Apixaban can be started directly or after a 1-2 day administration of parenteral anticoagulation (UFH, LMWH, or fondaparinux) 1, 2
Unlike vitamin K antagonists, apixaban can be initiated with minimal or no parenteral bridging 1, 7
The higher initial dose of apixaban (10 mg twice daily) for the first 7 days is designed to achieve rapid therapeutic anticoagulation 2, 7

All patients with PE should receive therapeutic anticoagulation for at least 3 months 5, 8
For patients with recurrent VTE not related to a major transient risk factor, indefinite oral anticoagulant treatment is recommended 5, 8

Apixaban should not be used in patients with severe renal impairment or those with antiphospholipid antibody syndrome 5
Apixaban should not be used during pregnancy or lactation 5

Delaying anticoagulation when PE is suspected in patients with intermediate to high clinical probability 1, 3
Failing to use the correct initial higher dose of apixaban (10 mg twice daily for 7 days) 2
Unnecessarily prolonging parenteral anticoagulation before transitioning to apixaban 1, 2
Not considering patient-specific factors such as renal function, weight, and drug interactions when selecting anticoagulation 5